NE

Neogen Corporation

NEOGHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$870.4M
-2.7% YoY
Net Income
-$7.9M
+99.3% YoY
EBITDA
$170.5M
+118.2% YoY
Free Cash Flow
$69.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 26 MACD Negative CrossoverHistogram -0.0593, negative momentum
Aug 25 MACD Negative CrossoverHistogram -0.0394, negative momentum
About Neogen Corporation

Headquartered within the healthcare sector, Neogen Corporation focuses on Medical Devices services and products. Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. At a $2.58B market cap, Neogen Corporation ranks as a mid-cap company within healthcare. It operates through Food Safety and Animal Safety segments.

Where NEOG stands vs its 150-day and 200-day moving averages

As of the August 26, 2026 close, NEOG finished 18.05% above its 150-day moving average ($9.86) and 27.21% above its 200-day moving average ($9.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is NEOG overbought or oversold?

At the August 26, 2026 close, NEOG's RSI(14) was 53.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.58B
Fwd P/E31.13
EPS$-0.04
Beta1.76
52W Change+109.0%
ROE-0.4%
Analysis

Neogen Corporation carries $812.6M in total debt against $185.5M in cash reserves — debt is roughly 4.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $69.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -0.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $822.4M (2023) to $870.4M (2026).

A beta of 1.76 means NEOG is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Neogen Corporation and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms